1GORNET JM,COUVE S,HASSANI Z,et al.Infliximab for refractory ulceratie colitis or indeterminate colitis:an open-label multicentre study[J].Aliment Phannacol,Ther,2003,18:175.
2OCHSENKUHN T,SACKMANN M,GOKE B.lnfliximab for acute,not steroid-refractory ulcerative colitis:a randomized pilot study[J].Eur J Gastroenterol Hepatol,2004,16:167.
3RUTGEERTS P,FEAGEN BG,OLSON A,et al.A randomized placebo-controlled trial of Infliximab therapy for active ulcerative colitis:ACT 1 trial[J].Gastroenterology,2005,128:A 689.
4SANDBORN WJ,RACHMILEWITZ D,HANAUER SB,et al.Infliximab induction and maintenance therapy for ulcerative colitis:ACT 2 trial[J].Gastroenterology,2005,128:A688.
5TRAVIS SPL,YAP LM,HAWKEY CJ,et al.RDP-58 is anovel and potentially effective oral therapy for ulcerative colitis[J].Inflamm Bowel Dis,2005,11:713.
6LOFBERG R,NEURATH M,OST A,et al.Topical NRκB p65 antisense oligonucleotides in patients with active distal colonic IBD.A randomized,controlled pilot trial[J].Gastroenterology,2002,122:A 60.
7FEAGEN B,McDONALD JWD,GREENBERG G,et al.An ascending dose trial of a humanized α4β7 antibody in ulcerative colitis[J].Gastroenterology,2000,118:(Supl.):A 874.
8FEAGEN B,GREENBERG GR,WILD G,et al.Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin[J].N Engl J Med,2005,128:A 74.
9VAN DEVENTER SJ,VOLFOVA M,FLISIAK R,et al.A phase 2 dose ranging,double-blind,placebo-controlled study of Alicaforsen enema in subjects with acute exacerbation of mild to moderate leftsided ulcerative colitis[J].Gastroenterology,2005,128:A 74.
10CLAESSENS C,VAN AS SCHE G,DALLE I,et al.Clinical improvement precedes mucosal healing in ulcerative colitis treated with anti-IL-2 agents[J].Gastroenterology,2002,122:A 31.
二级参考文献18
1Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler I,Huber C, Ferrone S. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001; 61:8647-8650.
2Ritz U, M0mburg F, Pilch H, Huber C, Maeurer MJ, Seliger B.Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 2001; 19:1211-1220.
3Dovhey SE, Ghosh NS, Wright KL. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.Cancer Res 2000; 60:5789-5796.
4Dressel R, Lubbers M, Waiter L, Herr W, Gunther E. Enhanced susceptibility to cytotoxic T lymphocytes without increase of MHC class. I antigen expression after conditional overexpression of heat shock protein 70 in target cells. Eur J Immunol 1999; 29:3925-3935.
5Chen D, Androlewicz MJ. Heat shock protein 70 moderately enhances peptide binding and transport by the.transporter associated with antigen processing. Immunol Lett 2001; 75:143-148.
6Kurokohchi K, Carrington IV[, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, Akatsuka T, Berzofsky JA. Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 1996;23:1181-1188.
7Alimonti J, Zhang QJ, Gabathuler R, Reid G, Chen SS, Jefferies WA. TAP expression provides a general method for improving the recognition of malignant cells in vivo. Nat Biotechnol 2000; 18:515-520.
8Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, Drexler LHuber C, Ferrone S.Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001; 61: 8647-8650.
9Seliger B, Bock M, Ritz U, Huber C. High frequency of a nonfunctional TAP1/LMP2 promoter polymorphism in human tumors. Int J Oncol 2002; 20:. 349-353.
10Cromme FV, Airey J, Heemels MT, Ploegh HL, Keating PJ, Stern PL, Meijer CJ, Walboomers JM. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med 1994; 179:335-340.
